熱門資訊> 正文
Moderna、默克公司发布mRNA癌症疫苗的有希望的数据
2026-06-02 04:53
- Moderna (MRNA) and Merck (MRK) said that the experimental cancer vaccine intismeran autogene plus Keytruda (pembrolizumab) led to a 49% decline in the risk of recurrence or death, and a 50% reduction in the risk of distant metastasis, compared to Keytruda alone, or death in patients with late-stage melanoma.
- The data is based on a median five-year follow-up of the phase 2 KEYNOTE-942/mRNA-4157-P201.
- Overall survival, an exploratory endpoint, also showed a positive trend.
- Enrolled patients had high-risk stage III/IV melanoma.
- Intismeran autogene, known as an mRNA-individualized neoantigen therapy, is also under investigation by the two companies for other tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma.
More on Moderna, Merck
- Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
- Merck & Co., Inc. (MRK) Shareholder/Analyst Call - Slideshow
- Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
- EU to target XFG variant for next COVID vaccines
- FDA to cut animal testing in cancer drug development
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
